R. Session
Director/Board Member bei Lung Therapeutics, Inc.
Profil
R.
A.
Session was the founder of Taysha Gene Therapies, Inc. founded in 2019, where he held the title of Director from 2022 to 2023.
Currently, he holds the position of Director at Lung Therapeutics, Inc. since 2019, and Director at ReCode Therapeutics, Inc., Sandhill Therapeutics, Inc., and is a Member of the Society of Kauffman Fellows.
In the past, he worked as Senior Director-Strategic Planning & Finance at Reata Pharmaceuticals, Inc., Independent Director at Chardan Healthcare Acquisition 2 Corp., Vice President-Commercial Development at PTC Therapeutics, Inc. from 2013 to 2017, SVP-Corporate Strategy & Business Development at Novartis Gene Therapies, Inc. from 2017 to 2018, Chief Business Officer & Head-Corporate Strategy at 4D Molecular Therapeutics, Inc. in 2018, and Chief Business Officer at BridgeBio Pharma, Inc. from 2019 to 2020.
Mr. Session's education includes a graduate degree and an MBA from Texas A&M University and an undergraduate degree from The University of North Carolina at Charlotte.
Aktive Positionen von R. Session
| Unternehmen | Position | Beginn |
|---|---|---|
Lung Therapeutics, Inc.
 Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Director/Board Member | 04.02.2019 |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Director/Board Member | - |
| Sandhill Therapeutics, Inc. | Director/Board Member | - |
Society of Kauffman Fellows
 Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services The Society of Kauffman Fellows is a venture capital fellowship program that aims to foster innovative leaders. The non-profit company is based in Palo Alto, CA. The program lasts for two years and includes industry events, summits, and a venture capital fund. The CEOs of the company are Jeff Harbach, Costello Trish. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von R. Session
| Unternehmen | Position | Ende |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Founder | 02.03.2023 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01.04.2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2018 |
| AVEXIS INC | Corporate Officer/Principal | 01.07.2018 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2017 |
Ausbildung von R. Session
| Texas A&M University | Graduate Degree |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Health Technology |
Society of Kauffman Fellows
Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services The Society of Kauffman Fellows is a venture capital fellowship program that aims to foster innovative leaders. The non-profit company is based in Palo Alto, CA. The program lasts for two years and includes industry events, summits, and a venture capital fund. The CEOs of the company are Jeff Harbach, Costello Trish. | Commercial Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition 2 Corp. operates as a blank check company, which engages in the acquisition of healthcare company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 19, 2018 and is headquartered in New York, NY. | Finance |
| Sandhill Therapeutics, Inc. |
